HRP970237B1 - Inclusion complexes of aryl-heterocyclic salts - Google Patents

Inclusion complexes of aryl-heterocyclic salts

Info

Publication number
HRP970237B1
HRP970237B1 HR970237A HRP970237A HRP970237B1 HR P970237 B1 HRP970237 B1 HR P970237B1 HR 970237 A HR970237 A HR 970237A HR P970237 A HRP970237 A HR P970237A HR P970237 B1 HRP970237 B1 HR P970237B1
Authority
HR
Croatia
Prior art keywords
aryl
inclusion complexes
heterocyclic salts
heterocyclic
salts
Prior art date
Application number
HR970237A
Other languages
English (en)
Inventor
Charles Kevin Johnson
Kim Yesook
Mysore Shanker Ravi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HRP970237A2 publication Critical patent/HRP970237A2/hr
Publication of HRP970237B1 publication Critical patent/HRP970237B1/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Soil Conditioners And Soil-Stabilizing Materials (AREA)
  • Seasonings (AREA)
  • Machine Translation (AREA)
HR970237A 1996-05-07 1997-05-07 Inclusion complexes of aryl-heterocyclic salts HRP970237B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1920496P 1996-05-07 1996-05-07

Publications (2)

Publication Number Publication Date
HRP970237A2 HRP970237A2 (en) 1998-12-31
HRP970237B1 true HRP970237B1 (en) 2002-04-30

Family

ID=21791976

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970237A HRP970237B1 (en) 1996-05-07 1997-05-07 Inclusion complexes of aryl-heterocyclic salts

Country Status (47)

Country Link
US (2) US6232304B1 (zh)
EP (1) EP0900088B1 (zh)
JP (1) JP3579060B2 (zh)
KR (1) KR20000010823A (zh)
CN (1) CN1216923A (zh)
AP (1) AP796A (zh)
AR (2) AR007002A1 (zh)
AT (1) ATE257714T1 (zh)
AU (1) AU713711B2 (zh)
BG (3) BG64474B1 (zh)
BR (1) BR9709213A (zh)
CA (1) CA2251912C (zh)
CO (1) CO4600677A1 (zh)
CZ (1) CZ297847B6 (zh)
DE (1) DE69727218T2 (zh)
DK (1) DK0900088T3 (zh)
DZ (1) DZ2220A1 (zh)
EA (1) EA001731B1 (zh)
EG (1) EG24135A (zh)
ES (1) ES2212809T3 (zh)
GE (1) GEP20074185B (zh)
GT (1) GT199700044A (zh)
HN (1) HN1997000039A (zh)
HR (1) HRP970237B1 (zh)
HU (1) HU222451B1 (zh)
ID (1) ID16866A (zh)
IL (1) IL126546A (zh)
IS (1) IS2524B (zh)
MA (1) MA24172A1 (zh)
ME (1) ME00880B (zh)
MY (1) MY121999A (zh)
NO (1) NO324373B1 (zh)
NZ (1) NZ332220A (zh)
OA (1) OA10907A (zh)
PL (1) PL189324B1 (zh)
PT (1) PT900088E (zh)
RS (1) RS49532B (zh)
SA (1) SA97180024B1 (zh)
SI (1) SI0900088T1 (zh)
SK (1) SK282032B6 (zh)
TN (1) TNSN97075A1 (zh)
TR (1) TR199802231T2 (zh)
TW (1) TW514529B (zh)
UA (1) UA57734C2 (zh)
UY (1) UY24544A1 (zh)
WO (1) WO1997041896A2 (zh)
ZA (1) ZA973874B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
EP0811386B1 (en) * 1996-05-07 2004-09-29 Pfizer Inc. Method of selecting a salt for making an inclusion complex
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) * 1999-05-10 2010-07-14 栄研化学株式会社 ホタルルシフェリンの安定化方法
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6884885B2 (en) * 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
BR0313602A (pt) * 2002-08-20 2005-06-21 Bristol Myers Squibb Co Método e formulação de complexo de aripiprazol
AU2003263413A1 (en) * 2002-09-17 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
RU2292207C2 (ru) * 2002-10-25 2007-01-27 Пфайзер Продактс Инк. Депо-препараты арилгетероциклических активных веществ в виде суспензии
PL377679A1 (pl) * 2002-10-25 2006-02-06 Pfizer Products Inc. Nowe preparaty typu depot do wstrzykiwania
US20040147532A1 (en) * 2002-10-31 2004-07-29 Pfizer Inc Liquid conjugates of solid pharmaceuticals
WO2004039411A2 (en) * 2002-10-31 2004-05-13 Pfizer Products Inc. Solid and semi-solid polymeric ionic conjugates
EP1418492B1 (en) * 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
EP1546146A1 (en) * 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
AU2004268663B2 (en) * 2003-09-02 2010-12-09 Pfizer Products Inc. Sustained release dosage forms of ziprasidone
CA2548491A1 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
EP1744750A2 (en) 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) * 2004-05-26 2006-03-30 Pfizer Products Inc. In vitro predictive method
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
JP5324098B2 (ja) * 2004-11-16 2013-10-23 アルケルメス ファーマ アイルランド リミテッド 注射可能なナノ粒子のオランザピン製剤
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20150081370A (ko) 2006-07-10 2015-07-13 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
KR20100017109A (ko) * 2007-05-18 2010-02-16 싸이도우스 엘엘씨. 지프라시돈 제제
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) * 2011-05-25 2014-12-17 上海医药工业研究院 卢拉西酮组合物
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1255462B (it) 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
EP0811386B1 (en) 1996-05-07 2004-09-29 Pfizer Inc. Method of selecting a salt for making an inclusion complex
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL126590A (en) 1996-05-07 2001-11-25 Pfizer Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
NO324373B1 (no) 2007-10-01
US6399777B2 (en) 2002-06-04
SI0900088T1 (en) 2004-04-30
AP796A (en) 1999-12-24
DK0900088T3 (da) 2004-04-19
HN1997000039A (es) 1997-06-26
TNSN97075A1 (fr) 2005-03-15
AR045528A2 (es) 2005-11-02
HU222451B1 (hu) 2003-07-28
IL126546A0 (en) 1999-08-17
BG64475B2 (bg) 2005-04-30
JPH11509866A (ja) 1999-08-31
HRP970237A2 (en) 1998-12-31
WO1997041896A3 (en) 1998-01-08
IL126546A (en) 2001-01-28
EA199800910A1 (ru) 1999-04-29
US6232304B1 (en) 2001-05-15
HUP9902799A2 (hu) 1999-12-28
RS49532B (sr) 2006-12-15
GEP20074185B (en) 2007-08-10
TW514529B (en) 2002-12-21
GT199700044A (es) 1998-10-02
ME00880B (me) 2006-12-15
AU1937297A (en) 1997-11-26
OA10907A (en) 2001-10-26
DZ2220A1 (fr) 2002-12-03
WO1997041896A2 (en) 1997-11-13
AU713711B2 (en) 1999-12-09
AR007002A1 (es) 1999-10-13
ZA973874B (en) 1998-11-06
ID16866A (id) 1997-11-20
ATE257714T1 (de) 2004-01-15
CA2251912A1 (en) 1997-11-13
HUP9902799A3 (en) 2000-12-28
MA24172A1 (fr) 1997-12-31
PT900088E (pt) 2004-04-30
YU17297A (sh) 1999-12-27
EP0900088A2 (en) 1999-03-10
NO985192D0 (no) 1998-11-06
CO4600677A1 (es) 1998-05-08
PL189324B1 (pl) 2005-07-29
DE69727218T2 (de) 2004-11-18
JP3579060B2 (ja) 2004-10-20
CZ297847B6 (cs) 2007-04-11
IS2524B (is) 2009-07-15
CA2251912C (en) 2003-06-03
EP0900088B1 (en) 2004-01-14
UY24544A1 (es) 2000-09-29
NZ332220A (en) 2000-03-27
PL329928A1 (en) 1999-04-26
US20010031756A1 (en) 2001-10-18
BR9709213A (pt) 1999-08-10
TR199802231T2 (xx) 1999-02-22
BG64474B1 (bg) 2005-04-30
ES2212809T3 (es) 2004-08-01
DE69727218D1 (de) 2004-02-19
BG64475B1 (bg) 2005-04-30
BG102894A (en) 1999-09-30
KR20000010823A (ko) 2000-02-25
AP9700977A0 (en) 1997-07-31
SA97180024B1 (ar) 2005-12-24
MY121999A (en) 2006-03-31
NO985192L (no) 1998-11-06
UA57734C2 (uk) 2003-07-15
EA001731B1 (ru) 2001-08-27
SK150498A3 (en) 2000-01-18
CZ346198A3 (cs) 1999-09-15
IS4880A (is) 1998-10-27
CN1216923A (zh) 1999-05-19
EG24135A (en) 2008-08-06
SK282032B6 (sk) 2001-10-08

Similar Documents

Publication Publication Date Title
AP9700977A0 (en) Inclusion complexes of aryl-heterocyclic salts
GB9711237D0 (en) Organomettallic Complexes
ZA972689B (en) 6-Phenylpyridyl-2-amine derivatives
ZA952413B (en) 3-aryl-4-hydroxy-delta3-dihydrothiophenone derivatives
AP9701156A0 (en) 6-phenylpyridyl-2-amine derivatives
GB9511077D0 (en) 17B-Substituted-6-azasteroid derivatives
EP0708091A3 (en) Indoloylguanidine derivatives
ZA953356B (en) Benzocycloalkylazolethione derivatives
EP0692482A3 (en) 1-pyridyltetrazolinone derivatives
HUP9701835A2 (hu) Vinil-pirrolidinon-cefalosporin-származékok
IL112519A0 (en) 5-heteroarylindole derivatives
GB9511365D0 (en) Pyridazino-indole derivatives
HU9503582D0 (en) Thienopyridon derivatives
HU9701479D0 (en) N-benzylazolium derivatives
GB9513342D0 (en) Complexes
GB9604996D0 (en) Benzodiazonine derivatives
GB9603226D0 (en) Heterocyclyl-ergoline derivatives
GB9600063D0 (en) Guaridine derivatives
ZA9510848B (en) Mutable composition
GB9702049D0 (en) Tetrahhydroisoquinoline derivatives
GB2291425B (en) 7-Diazo-beta-lactam derivatives
GB2287463B (en) Bis-anthracycline derivatives
HU9601036D0 (en) Aryl-sulfonyl-hydroxamic-acid derivatives
ZA958396B (en) Peptidyl compounds
AU123314S (en) Track

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160503

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20170507